Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
Monthly Recap: China Pharmaceutical Regulatory Updates | August 2023 China pharma regulatory updates in Aug 2023: 1. China Consults on Conditional Approval Process; 2. China Rolls out 71st and 72nd Lists of RLDs; 3. China Grants Two Rx-to-OTC Switches; 4. China Releases Pharmaceutical Guidelines; 5. China Consults on Drafts of Drug Standards
Sep 08, 2023
[Updated] GLP-1-RAs Swoop to Chinese Market, Eyeing Diabetes Treatment & Weight Control Needs On July 25, 2023, China National Medical Products Administration (NMPA) approved Beinaglutide Injection (Feisumei), a glucagon-like peptide-1 receptor agonist (GLP-1-RA), for weight loss.
Aug 23, 2023
Marketing Approval Priority Review Innovative Drug Generic Drug Biological Product Cancer Diabetes Drug Registration New DrugMonthly Report: New Drug Approvals in China | June 2023 In June 2023, China NMPA approved 33 new drugs, among which 26 are chemical drugs while 7 are biological products.
Jul 07, 2023
BaiPharm Shares Insights into Computational Toxicology with Pharma Professionals at CPHI China As CPHI China’s partner, BaiPharm staged a seminar “Application of Computational Toxicology in the Pharmaceutical Industry” which covers four sessions, each presented by experienced experts, on June 19, 2023.
Jun 25, 2023
Marketing Approval Innovative Drug Generic Drug Biological Product Cancer Diabetes Vaccine Drug Registration New DrugMonthly Report: New Drug Approvals in China | May 2023 In May 2023, China NMPA approved 27 new drugs, among which 16 are chemicals and 11 are biologics: 1. Betta Pharma’ Befotertinib Mesylate Capsules; 2. Sanhome Pharma’s Alfosbuvir Tablets; 3. Novartis’ Ribociclib Succinate Tablets...
Jun 12, 2023
Green Development: Not Merely Conceptual, But Compulsory for Pharma Manufacturing in China China is not advanced enough in regulations and technologies for green development, but the good news is that China has been making progress. China tends to turn guidelines into compulsory regulations, including setting up clearer standards for regulating pollution emission.
Apr 19, 2023
- [Updated] China Publishes the Preliminary List of Drugs for 2023 National Reimbursement Drug List (NRDL)
- [Updated] Biopharma Licensing Deals Involving Chinese Companies in H1 2023
- Drug Inspections of Manufacturers and Suppliers in China: Regulation Revised
- [Updated] GLP-1-RAs Swoop to Chinese Market, Eyeing Diabetes Treatment & Weight Control Needs
- Monthly Report: New Drug Approvals in China | July 2023